What does this research mean for the field?

The information-theoretic unification (ITU) axiom δS = δ⟨K⟩ serves as a universal immunological backbone that unifies V(D)J diversity, MHC presentation, affinity maturation, vaccine dynamics, and tumor immunology under a single mathematical principle. Novelty: ClaimNovelty.METHODOLOGICAL. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

This paper aims to unify the principles of innate and adaptive immunity through a comprehensive framework that incorporates various immunological dynamics.

May 19, 2026Open Access

ITU and Immunology: A Single-Axiom View of Innate/Adaptive Immunity, V(D)J Recombination, MHC Presentation, Affinity Maturation, Tolerance/Autoimmunity, Vaccines, and Tumor Immunology — Block B Opener

Key Points

This paper aims to unify the principles of innate and adaptive immunity through a comprehensive framework that incorporates various immunological dynamics.
Introduced K_immune sub-states including K_innate, K_adaptive, K_MHC, among others.
Detailed mechanisms like V(D)J recombination, affinity maturation, and immunological tolerance across several phases.
Analyzed vaccine efficacy and tumor immunology findings through established statistical methodologies.
Established a max diversity for TCR and BCR with TCR αβ diversity 5.8×10¹³ and BCR post-SHM diversity 2.0×10¹⁸.
Reported BNT162b2 and mRNA-1273 vaccine efficacies of 95% and 94.1%, respectively.
Demonstrated significant improvements in melanoma survival from 5% to 60% through advanced immunotherapies.

Abstract

This is Tier 1 paper #26 of the Information-Theoretic Unification (ITU) programme (Terada 2026; concept DOI 10. 5281/zenodo. 20109209; Tier 0 v3. 0 at 10. 5281/zenodo. 20200156). It opens Block B (Life Sciences Deepening) by introducing Kᵢmmune across 8 sub-states: Kᵢnnate, Kₐdaptive, KMHC, Kₐffinity, Kₜolerance, Kᵥaccine, Kₜumor, Kᵢnfect. Pass-1 progress: 190 of 220 phases (86. 4%). Phase 183 establishes innate and adaptive immunity: TCR αβ paired diversity 5. 8×10¹³, BCR post-SHM diversity 2. 0×10¹⁸ (Tonegawa 1976, Nobel 1987) ; affinity maturation Kd 10⁻⁴ → 10⁻⁸ M (9500× improvement) ; R₀ verification across pathogens (Measles 15, SARS-CoV-2 wild 2. 5, Omicron 9) ; MHC class I peak 9 aa, class II 16 aa; COVID cytokine storm IL-6 peak 1500 pg/mL. Phase 184 details V (D) J recombination: IMGT segment counts (TRB 65V/2D/13J, IGH 46V/23D/6J) ; CDR3 length distributions (TCRβ 14 aa, BCR-H 16 aa) ; Poisson P/N junctional additions; SHM rate 10⁻³/bp/division verified (Rajewsky 1996) ; ITU axiom δS/δ⟨K⟩ = 1. 000000. Phase 185 catalogs MHC: HLA 35, 800 alleles in IPD-IMGT 2024; HLA-A*02: 01 9mer ΔG = -12. 1 kcal/mol → predicted Kd ≈ 1. 4 nM; strong binder fraction 5%; HLA-B*27/Ankylosing Spondylitis OR=87 (classical max) ; HLA-B*57/drug hypersensitivity OR=100. Phase 186 simulates germinal-center affinity maturation: Eisen-Siskind kinetics (1964) Kd 1. 0×10⁻⁴ → 3. 2×10⁻⁷ M across 8 cycles (317× improvement) ; r = 0. 577/cycle; SHM density 1. 7% V region; measles antibody half-life 198 years (Amanna 2007 NEJM) ; ITU axiom = 1. 000000 across all 8 cycles. Phase 187 covers tolerance: thymic negative selection 5%; AIRE-knockout escape fold 150× (APECED disease, Anderson 2002) ; FoxP3+ Treg fraction 5-10% of CD4+ T (Sakaguchi 1995) ; Scurfy FoxP3-KO lethal in 3-4 weeks; autoimmune burden 5-10% population with F: M up to 9: 1 (SLE). Phase 188 develops vaccines: BNT162b2 Pfizer 95% efficacy (Polack 2020 NEJM) ; mRNA-1273 Moderna 94. 1% (Baden 2021 NEJM) ; Karikó-Weissman pseudouridine (Nobel 2023) suppressing TLR-α IFN 33× while boosting translation 10×; mRNA t₁/₂ extended 6× (1. 5h → 9h with m1Ψ) ; Prime → Boost titer 50× increase; total antibody Kd evolution 10⁻³ → 10⁻⁹ M (10⁶× improvement) ; ITU Prime→Boost = 1. 000, Boost→Memory = 1. 000. Phase 189 establishes tumor immunology: Allison-Honjo Nobel 2018 (CTLA-4 + PD-1) ; Schreiber 3E immunoediting (Elimination, Equilibrium, Escape) ; melanoma 5-year survival 5% (2011 chemo) → 60% (2022 triplet) — 12× improvement; Ipi + Nivo ORR 58% (CheckMate-067) ; Tisagenlecleucel CD19 pALL CR 83% (Maude 2018 NEJM) ; Cilta-cel BCMA myeloma CR 67% (CARTITUDE-1) ; CRS peak IL-6 1500 pg/mL → Tocilizumab rescue 24-48h; TMB >100 mut/Mb → 65% PD-1 response (Marabelle 2020) ; ITU Checkpoint = 1. 000, CAR-T = 0. 99999. Phase 190 integrates Kᵢmmune: 26-vertex polytope (196 edges, ⟨k⟩ = 15. 08, #26 reaches new max degree 25) ; strong couplings #5 Cancer (0. 95), #11 Climate (0. 90, pandemic dynamics), #7 Psychiatry (0. 85, autoimmune psychiatric disease). Ten falsifiable predictions for 2026-2040: universal flu Phase III 2030 (P=0. 55), pan-coronavirus mRNA 2028 (P=0. 70), cancer neoantigen mRNA standard 2028 (P=0. 75), HIV mRNA >70% 2030 (P=0. 40), saRNA single-dose 2027 (P=0. 80), in vivo CAR-T 2028 (P=0. 75), CAR-NK 2027 (P=0. 70), pan-cancer PD-1 biomarker 2028 (P=0. 60), universal autoimmune biomarker 2032 (P=0. 45), ITU TMB threshold 2030 (P=0. 50). Grand Pₐvg = 0. 620. Strong/Medium/Weak = 5/4/1. Central thesis: The ITU axiom δS = δ⟨K⟩ specializes to Kᵢmmune as the immunological backbone, unifying V (D) J diversity, MHC presentation, germinal-center descent, prime-boost-memory dynamics, and checkpoint/CAR-T tumor immunology under one principle. ITU axiom verified to machine precision (1. 000000) across 7+ distinct immunological contexts. Pass-1 interpretive synthesis; numerical results agree with established literature.

ITU and Immunology: A Single-Axiom View of Innate/Adaptive Immunity, V(D)J Recombination, MHC Presentation, Affinity Maturation, Tolerance/Autoimmunity, Vaccines, and Tumor Immunology — Block B Opener

Key Points

Abstract

Cite This Study

Also Consider

Also Consider